CN1600355A - 一种治疗慢性胃炎的药物及其制备方法 - Google Patents
一种治疗慢性胃炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN1600355A CN1600355A CN 03158368 CN03158368A CN1600355A CN 1600355 A CN1600355 A CN 1600355A CN 03158368 CN03158368 CN 03158368 CN 03158368 A CN03158368 A CN 03158368A CN 1600355 A CN1600355 A CN 1600355A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicinal liquid
- medicine
- concentrated solution
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title claims description 19
- 208000023652 chronic gastritis Diseases 0.000 title claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 92
- 239000007788 liquid Substances 0.000 claims description 67
- 230000000694 effects Effects 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 32
- 239000008187 granular material Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 241000756943 Codonopsis Species 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 6
- 239000000341 volatile oil Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 208000016644 chronic atrophic gastritis Diseases 0.000 abstract description 4
- 208000004300 Atrophic Gastritis Diseases 0.000 abstract description 3
- 208000036495 Gastritis atrophic Diseases 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 241000132012 Atractylodes Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 35
- 238000012360 testing method Methods 0.000 description 30
- 210000002784 stomach Anatomy 0.000 description 27
- 210000002105 tongue Anatomy 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 21
- 230000036407 pain Effects 0.000 description 15
- 206010012735 Diarrhoea Diseases 0.000 description 14
- 230000036528 appetite Effects 0.000 description 13
- 235000019789 appetite Nutrition 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 206010000087 Abdominal pain upper Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 235000019658 bitter taste Nutrition 0.000 description 7
- 208000037976 chronic inflammation Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010013781 dry mouth Diseases 0.000 description 7
- 206010003549 asthenia Diseases 0.000 description 6
- 230000009429 distress Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 235000021266 loss of appetite Nutrition 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000004206 stomach function Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 230000004596 appetite loss Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000019017 loss of appetite Diseases 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000002575 gastroscopy Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 206010034754 petechiae Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 244000257039 Duranta repens Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035620 dolor Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/Kg) | 动物只数 | 药后增重% |
正常组 | 等量常水 | 9 | 14.33 |
模型组 | 等量常水 | 12 | 9.24 |
胃宁组 | 15 | 12 | 24.17 |
本发明药物浸膏液组 | 8 | 12 | 21.70 |
4 | 12 | 26.71 | |
2 | 12 | 20.62 |
组别 | 剂量(g/kg) | 动物数(只) | 胃蛋白酶活性(ug/ml·min-1) | 总酸度(mmol/L) | 胰脂肪酶(v/ml) | 胰淀粉酶(v/ml) |
正常组 | 等量常水 | 9 | 1.12±0.23 | 95±31 | 7.21±1.42 | 1157.4±136 |
模型组 | 等量常水 | 12 | 0.71±0.26ΔΔ | 77±26 | 5.25±1.40ΔΔ | 845.1±212ΔΔ |
胃宁组 | 15 | 12 | 0.96±0.10* | 107±13** | 7.03±1.69** | 1134.7±145** |
本发明药物浸膏组 | 8 | 12 | 0.98±0.12* | 113±12** | 6.70±0.67** | 1178.9±97.8** |
4 | 12 | 1.03±0.18** | 105±14** | 8.60±1.41** | 1044.1±270* | |
2 | 12 | 0.88±0.33 | 87±20 | 8.11±1.45** | 964.2±264 |
黄芪 | 党参 | 白术 | 仙鹤草 | 黄芩 | 丹参 | 白芍 | 枳壳 | 檀香 | 甘草 |
3 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 0.3 | 1 |
4.5 | 3 | 3 | 3 | 3 | 4.5 | 3 | 3 | 0.45 | 1.5 |
1.5 | 1 | 1 | 1 | 1 | 1.5 | 1 | 1 | 0.15 | 0.5 |
6 | 4 | 4 | 4 | 4 | 6 | 4 | 4 | 0.6 | 2 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031583687A CN1330334C (zh) | 2003-09-26 | 2003-09-26 | 一种治疗慢性胃炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031583687A CN1330334C (zh) | 2003-09-26 | 2003-09-26 | 一种治疗慢性胃炎的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1600355A true CN1600355A (zh) | 2005-03-30 |
CN1330334C CN1330334C (zh) | 2007-08-08 |
Family
ID=34660451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031583687A Expired - Lifetime CN1330334C (zh) | 2003-09-26 | 2003-09-26 | 一种治疗慢性胃炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1330334C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104606418A (zh) * | 2013-11-05 | 2015-05-13 | 王殿家 | 一种治疗各种胃炎及消化不良的中药组合物 |
CN109303848A (zh) * | 2018-12-06 | 2019-02-05 | 陕西中医药大学 | 一种用于防治慢性萎缩性胃炎癌前病变的药物组合物 |
CN112587578A (zh) * | 2020-12-30 | 2021-04-02 | 江苏天晟药业股份有限公司 | 一种含有甘草的中药组和物的配方和制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094959A (zh) * | 1993-05-13 | 1994-11-16 | 山东省医学科学院基础医学研究所 | 一种治疗胃病的中药 |
CN1201772C (zh) * | 2002-07-26 | 2005-05-18 | 杨唐玉 | 治疗慢性萎缩性胃炎的中药制剂 |
-
2003
- 2003-09-26 CN CNB031583687A patent/CN1330334C/zh not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104606418A (zh) * | 2013-11-05 | 2015-05-13 | 王殿家 | 一种治疗各种胃炎及消化不良的中药组合物 |
CN109303848A (zh) * | 2018-12-06 | 2019-02-05 | 陕西中医药大学 | 一种用于防治慢性萎缩性胃炎癌前病变的药物组合物 |
CN112587578A (zh) * | 2020-12-30 | 2021-04-02 | 江苏天晟药业股份有限公司 | 一种含有甘草的中药组和物的配方和制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1330334C (zh) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1247240C (zh) | 用于治疗过敏性鼻炎的草药组合物及其用途 | |
CN1712048A (zh) | 一种治疗气滞胃痛的中药及其制备方法 | |
CN1709497A (zh) | 一种苗药组合物及其应用 | |
CN1686267A (zh) | 一种温经养血的中药制剂及其制备方法 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1600355A (zh) | 一种治疗慢性胃炎的药物及其制备方法 | |
CN1733279A (zh) | 一种治疗慢性肾衰的药物复合物 | |
CN1245189C (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1698709A (zh) | 一种复方黄芩制剂 | |
CN1323689C (zh) | 一种治疗前列腺增生的药物及其制备方法 | |
CN1290553C (zh) | 一种治疗月经过多的药物组合物及其制备方法 | |
CN1593583A (zh) | 治疗骨折的复方制剂及其制备方法 | |
CN1679802A (zh) | 一种壮腰健肾制剂和制备方法 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1698716A (zh) | 一种止痛祛瘀的妇科中药制剂 | |
CN1803162A (zh) | 一种治疗鼻科疾病的药物组合物及其制备方法 | |
CN1322111A (zh) | 治疗男性阳痿的天然茶及其制备方法 | |
CN1112439A (zh) | 治疗糖尿病的中药及其生产方法 | |
CN1596939A (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN1296080C (zh) | 清肝降压胶囊及其制备方法 | |
CN1726934A (zh) | 血府逐瘀药物组合物在制备降血脂药物中的应用 | |
CN1634503A (zh) | 一种治疗胃痛的药物组合物、制备方法及其用途 | |
CN1745808A (zh) | 一种慢性前列腺炎的中药组合物及其制备方法 | |
CN1698715A (zh) | 一种清热安胎中药及其制备方法 | |
CN1634353A (zh) | 一种治疗脉管炎、硬皮病及动脉硬化性下肢血管闭塞症药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HEFEI LIFEON MEDICATION CO., LTD. Free format text: FORMER NAME: LIFANG PHARMACEUTICAL MFG. CO, LTD, HEFEI |
|
CP03 | Change of name, title or address |
Address after: 230088 No. 669 Changjiang West Road, Hefei Patentee after: HEFEI LIFEON PHARMACEUTICAL Co.,Ltd. Address before: 230088 Huayuan Industrial Park, 669 West Changjiang Road, Anhui, Hefei Patentee before: Hefei Lifeon Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230625 Address after: 230601 Tangkou road and qingluan intersection, economic and Technological Development Zone, Hefei, Anhui Province Patentee after: Hefei Chengbiopharmaceutical Co.,Ltd. Address before: Cubic Plant Area, No. 669, Changjiang West Road, Hefei Patentee before: HEFEI LIFEON PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CI03 | Correction of invention patent |
Correction item: transfer of patent right Correct: HEFEI CHENGZHI BIO-PHARMACEUTICAL Co.,Ltd.|230601 Tangkou road and qingluan intersection, economic and Technological Development Zone, Hefei, Anhui Province False: Hefei Chengbiopharmaceutical Co.,Ltd.|230601 Tangkou road and qingluan intersection, economic and Technological Development Zone, Hefei, Anhui Province Number: 27-01 Volume: 39 |
|
CI03 | Correction of invention patent | ||
CX01 | Expiry of patent term |
Granted publication date: 20070808 |
|
CX01 | Expiry of patent term |